With a fresh $100M in hand, one RNA startup is moving to the clinic, finding partners and building a new lab — all at once
Until 2020, Camp4 was in the business of creating maps of how cells turn genes on and off.
But then it changed course. “Following the biology” of its scientific co-founder Rick Young, as CEO Josh Mandel-Brehm put it, the startup began working with regulatory RNAs, or regRNAs for short. In August, it netted $45 million in new funding to figure out how to drug these regRNAs.
Today, not even a year after its last financing, the biotech announced a $100 million Series B. The money will go toward getting regRNA drugs to the clinic for two indications — first in Dravet syndrome, a genetic form of epilepsy, which the biotech hopes to file an IND for early next year, and second in urea cycle disorders, in which ammonia builds up to toxic levels in the liver.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.